tetano
Editor, Senior Moderator
Viruses. 2020 Feb 2;12(2). pii: E167. doi: 10.3390/v12020167. [h=1]A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs.[/h]
Park JG[SUP]1[/SUP], Ye C[SUP]1[/SUP], Piepenbrink MS[SUP]2[/SUP], Nogales A[SUP]1,[/SUP][SUP]3[/SUP], Wang H[SUP]4[/SUP], Shuen M[SUP]4[/SUP], Meyers AJ[SUP]5[/SUP], Martinez-Sobrido L[SUP]1[/SUP], Kobie JJ[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Although seasonal influenza vaccines block most predominant influenza types and subtypes, humans still remain vulnerable to waves of seasonal and new potential pandemic influenza viruses for which no immunity may exist because of viral antigenic drift and/or shift. Previously, we described a human monoclonal antibody (hMAb), KPF1, which was produced in human embryonic kidney 293T cells (KPF1-HEK) with broad and potent neutralizing activity against H1N1 influenza A viruses (IAV) in vitro, and prophylactic and therapeutic activities in vivo. In this study, we produced hMAb KPF1 in tobacco plants (KPF1-Antx) and demonstrated how the plant-produced KPF1-Antx hMAb possesses similar biological activity compared with the mammalian-produced KPF1-HEK hMAb. KPF1-Antx hMAb showed broad binding to recombinant HA proteins and H1N1 IAV, including A/California/04/2009 (pH1N1) in vitro, which was comparable to that observed with KPF1-HEK hMAb. Importantly, prophylactic administration of KPF1-Antx hMAb to guinea pigs prevented pH1N1 infection and transmission in both prophylactic and therapeutic experiments, substantiating its clinical potential to prevent and treat H1N1 infections. Collectively, this study demonstrated, for the first time, a plant-produced influenza hMAb with in vitro and in vivo activity against influenza virus. Because of the many advantages of plant-produced hMAbs, such as rapid batch production, low cost, and the absence of mammalian cell products, they represent an alternative strategy for the production of immunotherapeutics for the treatment of influenza viral infections, including emerging seasonal and/or pandemic strains.
[h=4]KEYWORDS:[/h] antibody treatment; antivirals; influenza virus; monoclonal antibody; neutralizing antibody; orthomyxovirus; plantibody; prophylactic; therapeutic; virus infection; virus transmission
PMID: 32024281 DOI: 10.3390/v12020167
Free full text
Park JG[SUP]1[/SUP], Ye C[SUP]1[/SUP], Piepenbrink MS[SUP]2[/SUP], Nogales A[SUP]1,[/SUP][SUP]3[/SUP], Wang H[SUP]4[/SUP], Shuen M[SUP]4[/SUP], Meyers AJ[SUP]5[/SUP], Martinez-Sobrido L[SUP]1[/SUP], Kobie JJ[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Although seasonal influenza vaccines block most predominant influenza types and subtypes, humans still remain vulnerable to waves of seasonal and new potential pandemic influenza viruses for which no immunity may exist because of viral antigenic drift and/or shift. Previously, we described a human monoclonal antibody (hMAb), KPF1, which was produced in human embryonic kidney 293T cells (KPF1-HEK) with broad and potent neutralizing activity against H1N1 influenza A viruses (IAV) in vitro, and prophylactic and therapeutic activities in vivo. In this study, we produced hMAb KPF1 in tobacco plants (KPF1-Antx) and demonstrated how the plant-produced KPF1-Antx hMAb possesses similar biological activity compared with the mammalian-produced KPF1-HEK hMAb. KPF1-Antx hMAb showed broad binding to recombinant HA proteins and H1N1 IAV, including A/California/04/2009 (pH1N1) in vitro, which was comparable to that observed with KPF1-HEK hMAb. Importantly, prophylactic administration of KPF1-Antx hMAb to guinea pigs prevented pH1N1 infection and transmission in both prophylactic and therapeutic experiments, substantiating its clinical potential to prevent and treat H1N1 infections. Collectively, this study demonstrated, for the first time, a plant-produced influenza hMAb with in vitro and in vivo activity against influenza virus. Because of the many advantages of plant-produced hMAbs, such as rapid batch production, low cost, and the absence of mammalian cell products, they represent an alternative strategy for the production of immunotherapeutics for the treatment of influenza viral infections, including emerging seasonal and/or pandemic strains.
[h=4]KEYWORDS:[/h] antibody treatment; antivirals; influenza virus; monoclonal antibody; neutralizing antibody; orthomyxovirus; plantibody; prophylactic; therapeutic; virus infection; virus transmission
PMID: 32024281 DOI: 10.3390/v12020167
Free full text